TopBP1-IN-5
TopBP1-IN-5 is a TopBP1-BRCT7/8 inhibitor (IC50=2.47-3.8 nM). TopBP1-IN-5 selectively disrupts the interaction of TopBP1-BRCT7/8 with E2F1, mutp53, MIZ1, PLK1, CIP2A, and Top2A, without affecting BRCT1/2- and BRCT5-mediated interactions. TopBP1-IN-5 activates caspase-3/7 and caspase-8 to induce prometaphase arrest, mitotic catastrophe, and apoptosis, while inhibiting the MYC transcriptional program and enhancing the binding of MIZ1 to the p21Cip1 promoter. TopBP1-IN-5 exhibits broad-spectrum anticancer activity in triple-negative breast cancer, ovarian cancer, lung cancer, and acute myeloid leukemia models, and can be used for research on related cancers.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- CAS. Nr.: 896074-75-2
- Formel: C21H22N2O3
- Molecular Weight:350.41
-
Speicherung:
Please store the product under the recommended conditions in the Certificate of Analysis.
Alle Caspase Isoform-spezifische Produkte anzeigen
MoreAlle Topoisomerase Isoform-spezifische Produkte anzeigen
More
Biologische Aktivität
Beschreibung
In Vitro
TopBP1-IN-5 (3B6) (5 μM; 20 h) induces apoptosis in MDA-MB-468 and MDAH-2774 cells but not in nontransformed AML12 hepatocytes[1].
TopBP1-IN-5 (10 μM) induces PARP1 cleavage in MDAH-2774 cells[1].
TopBP1-IN-5 (20-100 μM) directly binds to TopBP1-BRCT7/8, inducing a 2 to 3°C thermal shift[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:MDA-MB-468, MDAH-2774, AML12
-
Concentration:5 μM
-
Incubation Time:20 h
-
Result:Induced apoptosis in MDA-MB-468 and MDAH-2774 cells as indicated by caspase-3/7 activity.
Had no effect in nontransformed AML12 mouse hepatocytes.
In Vivo
TopBP1-IN-5 (30 mg/kg; i.p.; three times per week; 17 days) significantly reduces the growth of Osimertinib (HY-15772)-resistant H1975-OsiR tumors in vivo[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) (female, BCM2665 PDX model)[1]
-
Dosage:40 mg/kg (efficacy); 15, 30, 45, or 60 mg/kg (dose-response)
-
Administration:i.p.; twice weekly (40 mg/kg) or three times per week (dose-response); 15 days (40 mg/kg) or 3 weeks (dose-response)
-
Result:Significantly suppressed tumor growth at 40 mg/kg twice weekly.
Induced apoptosis as evidenced by increased PARP1 cleavage in tumors.
Did not induce apoptosis or alter Ki-67 staining in intestinal crypts.
Increased the thermal stability (Tm) of TopBP1 protein in xenograft tumor tissues.
Showed dose-dependent in vivo antitumor activity with doses up to 60 mg/kg tolerated well and no plateau in efficacy observed.
-
Animal Model:NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG)[1]
-
Dosage:30 mg/kg
-
Administration:i.p.; three times per week; 17 days
-
Result:Significantly reduced the growth of H1975-OsiR tumors.
Did not alter Ki-67 staining or trigger apoptosis in mouse intestinal crypts.
Chemical Information
-
CAS. Nr. 896074-75-2
-
Molecular Weight 350.41
-
Formel C21H22N2O3
-
SMILES
CN1CCN(CC1)CC2=CC(=O)OC3=C2C=C(C(=C3)C4=CC=CC=C4)O
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Please store the product under the recommended conditions in the Certificate of Analysis.
Protokoll
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Breast Cancer Modeling
Breast cancer is a heterogeneous cancer, and it has been distinguished into four subtypes: luminal A, luminal B, HER2-positive and basal-like. Molecular mutations, epigenetic alterations, hormone exposure and immune microenvironment are related to the progression of breast cancer.
Reinheit & Dokumentation
Verweise
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)